IBERE PHARMACEUTICALS's ticker is IBERWS and the CUSIP is G46843119. A total of 23 filers reported holding IBERE PHARMACEUTICALS in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $2,083 | -90.1% | 212,500 | 0.0% | 0.00% | – |
| Q3 2022 | $21,000 | +40.0% | 212,500 | 0.0% | 0.00% | – |
| Q2 2022 | $15,000 | -61.5% | 212,500 | 0.0% | 0.00% | – |
| Q1 2022 | $39,000 | -65.8% | 212,500 | 0.0% | 0.00% | -100.0% |
| Q4 2021 | $114,000 | -6.6% | 212,500 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $122,000 | -23.8% | 212,500 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $160,000 | – | 212,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynwood Capital Management Inc. | 9,800 | $108,054 | 0.10% |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |